What this trial studies
Therapeutic touch intervention Participants in the therapeutic touch group received eight sessions over four weeks (two sessions per week), with each session lasting approximately 20 minutes. The intervention was conducted by a researcher trained in therapeutic touch following a standardized protocol. The session began with a centering phase lasting approximately 2-3 minutes, during which the practitioner focused attention through controlled breathing and mental concentration. This was followed by an energy field assessment lasting approximately 5-7 minutes, during which the practitioner held the hands 5-10 cm above the body without direct contact and slowly moved from the head toward the feet to assess the energy field.
Conditions in scope
- Depressive Symptoms Mild to Moderate in Severity
Interventions
- Therapeutic touch intervention (Other) — Participants in the therapeutic touch group received eight sessions over four weeks (two sessions per week), with each session lasting approximately 20 minutes. The intervention was conducted by a researcher trained in therapeutic touch following a standardized protocol. The session…
- Acupressure intervention (Other) — Participants in the therapeutic touch group received eight sessions over four weeks (two sessions per week), with each session lasting approximately 20 minutes. The intervention was conducted by a researcher trained in therapeutic touch following a standardized protocol. The session…
Who can join
Women only · Ages 45 Years to 65 Years · Accepts healthy volunteers.
Inclusion criteria
- Female participants aged 45 to 65 years
- Postmenopausal women
- Able to understand and respond to the data collection tools
- Willing to participate voluntarily
- Able to provide written informed consent
Exclusion criteria
- Younger than 45 years or older than 65 years
- Receiving hormone replacement therapy
- Having any psychiatric diagnosis
- Using psychiatric medication
- Having any condition that impairs the ability to understand or respond to the study questionnaires
- Refusing to participate in the study
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Osmaniye | Osmaniye Korkut Ata University | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2025-11-03
- Primary completion: 2026-01-10
- Last update posted: 2026-04-20
- First posted: 2026-04-16
Sponsor & contact
Lead sponsor: Osmaniye Korkut Ata University (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Conclusion (From baseline to 4 weeks)
The primary outcome measure of this study is the change in depressive symptom levels in postmenopausal women. Depressive symptoms will be assessed using the Beck Depression Inventory (BDI), a 21-item self-report scale in which each item is scored from 0 to 3. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms. A BDI score…
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07532512 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.